Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Tech Transfer regular column feature image

Below is Scrip’s regular roundup, including information from Strategic Transactions, of recent technology transfer agreements between companies and academic or other research institutions.

Tonix Pharmaceuticals Holding Corp. added to its post-traumatic stress disorder (PTSD) portfolio on 20 August by licensing a preclinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip